Best Practice Approach to Successful Conversion of Fosaprepitant to Aprepitant IV in a Large Multisite Community Oncology Infusion Center: A Retrospective Analysis
Crossref DOI link: https://doi.org/10.1007/s12325-020-01377-z
Published Online: 2020-05-23
Published Print: 2020-07
Update policy: https://doi.org/10.1007/springer_crossmark_policy
Burns, Derek
Kula, Julianna
Marshall, Scott
Ashworth, Elizabeth
Ornelas, Matthew
Funding for this research was provided by:
Heron Therapeutics, Inc.
Text and Data Mining valid from 2020-05-23
Version of Record valid from 2020-05-23
Article History
Received: 5 April 2020
First Online: 23 May 2020